



At IDRI, our mission is to translate science into global health solutions. We develop vaccines, diagnostics, and therapeutic products that address the world's most neglected infectious diseases.

Thomas Vedvick, PhD

Director, Process Sciences

Thomas Vedvick is the Director of Process Sciences at IDRI. Tom's research interests are focused on the development of large scale protein purification and the characterization of proteins for vaccine development. In addition, Tom directs the exciting adjuvant formulation program at IDRI. He has more than 70 original articles, and holds 28 issued U.S. patents for diagnostics, vaccines, and therapeutics of infectious diseases and cancer.

Prior to joining IDRI, Tom worked at the Salk Institute Biotechnology Industrial Associates (SIBIA) where he led the protein purification and characterization laboratory. While at SIBIA he collaborated on the development of the *Pichia pastoris* recombinant protein expression system. Tom later left SIBIA to work at Telios Pharmaceuticals, where he developed peptide based products for wound healing. Tom then joined Corixa Corporation where he established a protein microsequencing facility and directed the process development group which focused on vaccines for infectious diseases and cancer. Afterwards, Tom spent two years working at LigoCyte pharmaceuticals, where he served as Director of Process Development and Project Leader in the Norovirus vaccine program. He led the development of purification methods, formulation, and cGMP contract manufacturing of the Norovirus, Virus Like Particles. This successful program was the first product that reached a phase I clinical trial for LigoCyte Pharmaceutical.

Tom obtained his BSc in Chemistry from the University of Puget Sound, his MSc in Chemistry from Western Washington State University, and his PhD in Biochemistry from Oregon Health Sciences University. Tom's